- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05687877
Evusheld Japan PMS_Japan Post-Marketing Surveillance (PMS)
General Drug Use-Result Study of Evusheld Intramuscular Injection Set (Treatment and Prevention of Symptomatic Disease Caused by SARS-CoV-2 Infection)
Study Overview
Status
Conditions
Detailed Description
To investigate intends to evaluate the incidence of adverse drug reactions (ADRs) in individuals who receive Evusheld in clinical practice to determine its post-marketing safety profile in Japanese.
The investigation will be conducted as the addtional pharmacovigilance activitiy specified in the Japan Risk Management Plan (J-RMP) of Evusheld in compliance with the Ministerial Ordinance on Good Post-marketing Study Practice (GPSP Ordinance) and for the purpose of application for re-examination under Article 14-4 of the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (PMD Act).
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: AstraZeneca Clinical Study Information Center
- Phone Number: 1-877-240-9479
- Email: information.center@astrazeneca.com
Study Locations
-
-
-
Aichi, Japan
- Active, not recruiting
- Research Site
-
Aichi, Japan
- Recruiting
- Research Site
-
Chiba, Japan
- Recruiting
- Research Site
-
Fukuoka, Japan
- Recruiting
- Research Site
-
Fukuoka, Japan
- Withdrawn
- Research Site
-
Fukushima, Japan
- Recruiting
- Research Site
-
Gifu, Japan
- Active, not recruiting
- Research Site
-
Hiroshima, Japan
- Active, not recruiting
- Research Site
-
Hokkaido, Japan
- Recruiting
- Research Site
-
Hyogo, Japan
- Recruiting
- Research Site
-
Ibaraki, Japan
- Recruiting
- Research Site
-
Ishikawa, Japan
- Recruiting
- Research Site
-
Iwate, Japan
- Active, not recruiting
- Research Site
-
Kagoshima, Japan
- Recruiting
- Research Site
-
Kagoshima, Japan
- Withdrawn
- Research Site
-
Kanagawa, Japan
- Active, not recruiting
- Research Site
-
Kumamoto, Japan
- Withdrawn
- Research Site
-
Kyoto, Japan
- Recruiting
- Research Site
-
Kyoto, Japan
- Completed
- Research Site
-
Mie, Japan
- Completed
- Research Site
-
Nagasaki, Japan
- Active, not recruiting
- Research Site
-
Nara, Japan
- Recruiting
- Research Site
-
Nara, Japan
- Active, not recruiting
- Research Site
-
Niigata, Japan
- Withdrawn
- Research Site
-
Oita, Japan
- Withdrawn
- Research Site
-
Okayama, Japan
- Active, not recruiting
- Research Site
-
Okayama, Japan
- Withdrawn
- Research Site
-
Osaka, Japan
- Active, not recruiting
- Research Site
-
Osaka, Japan
- Terminated
- Research Site
-
Osaka, Japan
- Recruiting
- Research Site
-
Tokyo, Japan
- Recruiting
- Research Site
-
Tokyo, Japan
- Active, not recruiting
- Research Site
-
Tokyo, Japan
- Withdrawn
- Research Site
-
Tottori, Japan
- Recruiting
- Research Site
-
Yamanashi, Japan
- Active, not recruiting
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- For treatment of symptomatic disease caused by SARS-CoV-2 infection; Patients with risk factors for severe SARS-CoV-2 infection who do not require supplemental oxygen.
- For prevention of symptomatic disease caused by SARS-CoV-2 infection; Individuals for whom SARS-CoV-2 vaccination is not recommended OR those who are considered to have an inadequate response to a COVID-19 vaccine due to immunodeficiencies AND who is not close contacts such as family members or other people living in the same dwelling as patients infected with SARS-CoV-2.
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of ADRs
Time Frame: 24weeks(6 months)
|
The incidence of ADRs related to Evusheld Safety Specification; anaphylaxis and other serious allergic reactions, cardiovascular events
|
24weeks(6 months)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Toshimitsu Tokimoto, AstraZeneca KK
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D8850C00019
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.All request will be evaluated as per the AZ disclosure commitment.
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on SARS-CoV-2 Infection
-
St. Olavs HospitalThe Research Council of Norway; Helse Nord-Trøndelag HF; Alesund Hospital; Namsos... and other collaboratorsCompletedSARS-CoV-2 Acute Respiratory Disease | SARS-CoV-2 Sepsis | SARS CoV 2 InfectionNorway
-
Boston UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Burnet Institute and other collaboratorsRecruitingSARS CoV 2 Infection | SARS CoV 2 VaccinationUnited States, Malawi
-
Argorna Pharmaceuticals Co., LTDCompleted
-
Argorna Pharmaceuticals Co., LTDCompleted
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Active, not recruiting
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...Active, not recruiting
-
Arcturus Therapeutics, Inc.Terminated
-
University Hospital Inselspital, BerneUniversity of Bern; Lucerne University of Applied Sciences and ArtsCompleted
-
Centre Hospitalier Universitaire DijonUnknown
-
AIM Vaccine Co., Ltd.Zhejiang Provincial Center for Disease Control and PreventionNot yet recruiting